| Literature DB >> 31248405 |
Stephen Morrell1, Jane Young2, David Roder3.
Abstract
BACKGROUND: Primary and secondary healthcare service usage is assessed in the year before and following a cancer diagnosis, in cancer cases versus matched non-cancer controls in New South Wales (NSW), Australia over 2006-2012, for all invasive cancers collectively and for selected common sites: breast, prostate, colorectal and lung, and melanoma.Entities:
Keywords: Cancer; General practitioners; Health system usage; Hospital emergency departments; Specialists
Mesh:
Year: 2019 PMID: 31248405 PMCID: PMC6598375 DOI: 10.1186/s12913-019-4280-1
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Proportions and odds ratios of general practitioner and consultant/specialist episode of care, 12 months pre- and post-cancer diagnosis, all cancers, melanomas, and breast, colorectal, lung and prostate cancers. Note: the index diagnosis month is labelled ‘1’ to indicate service episodes occurring in the month including the date of diagnosis, with ‘-1’, 2, etc, indicating services occurring in the months before and after the diagnosis month
Fig. 2Proportions and odds ratios of hospital emergency department (ED) day visit and admission from ED, 12 months pre- and post-cancer diagnosis, all cancers, melanomas, and breast, colorectal, lung and prostate cancers. Note: the index diagnosis month is labelled ‘1’ to indicate service episodes occurring in the month including the date of diagnosis, with ‘-1’, 2, etc, indicating services occurring in the months before and after the diagnosis month
Mean monthly general practitioner, consultant/specialist episodes and hospital emergency department presentations for treatment or hospital admission in 12 months pre- and post-cancer diagnosis, major and all cancers diagnosed in 45 and Up cohort, 2006–12
|
| Yes/No | General | Consultant/ | ED | Admission | ||||
|---|---|---|---|---|---|---|---|---|---|
| Practitioner | Specialist | treatment | from ED | ||||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | ||
| Breast | Yes | 0.40x | 3.04*** | 0.05 | 0.10*** | 0.011 | 0.030*** | 0.008 | 0.024*** |
| No | 0.38 | 0.38 | 0.05 | 0.05* | 0.011 | 0.011 | 0.007 | 0.008* | |
| Colorectal | Yes | 0.61xxx | 1.68*** | 0.09xxx | 0.13*** | 0.018xxx | 0.032*** | 0.026xxx | 0.060*** |
| No | 0.51 | 0.50 | 0.07 | 0.07*** | 0.014 | 0.014 | 0.011 | 0.013** | |
| Lung | Yes | 0.73xxx | 2.54*** | 0.14xxx | 0.15 | 0.026xxx | 0.047*** | 0.037xxx | 0.134*** |
| No | 0.51 | 0.49*** | 0.07 | 0.07 | 0.013 | 0.014 | 0.011 | 0.014*** | |
| Melanoma | Yes | 0.61xxx | 1.05*** | 0.07xxx | 0.07 | 0.012 | 0.018*** | 0.010 | 0.016*** |
| No | 0.45 | 0.45 | 0.06 | 0.07*** | 0.011 | 0.013** | 0.009 | 0.011* | |
| Prostate | Yes | 0.51xxx | 2.11*** | 0.08xxx | 0.11*** | 0.016xxx | 0.022*** | 0.010 | 0.020*** |
| No | 0.47 | 0.47 | 0.07 | 0.07*** | 0.012 | 0.013* | 0.010 | 0.012*** | |
| All | Yes | 0.59xxx | 2.11*** | 0.08xxx | 0.10*** | 0.018xxx | 0.029*** | 0.020xxx | 0.049*** |
| No | 0.47 | 0.46*** | 0.06 | 0.07*** | 0.012 | 0.013*** | 0.010 | 0.012*** | |
Significance (by t-test): post-diagnosis compared to pre-diagnosis (*); cancer compared to non-cancer, pre-diagnosis (x):
***/xxxp <.0001
**/xx.0001 ≤p≤.001
*/x.001